Related Experiment Video
Updated: Jul 11, 2026
08:47
Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
Published on: December 7, 2017
Ghrelin, obesity and diabetes
Petra Wiedmer1, Rubén Nogueiras, Fabio Broglio
1Department of Pharmacology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Nuthetal, Germany.
Nature Clinical Practice. Endocrinology & Metabolism
|September 26, 2007
Summary
Ghrelin, a stomach peptide, influences appetite and body weight, and may impact glucose metabolism. Targeting the ghrelin system offers potential for new obesity and diabetes drugs.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Rising obesity and diabetes rates increase morbidity and mortality.
- Ghrelin, a stomach peptide, regulates food intake and body weight.
- Emerging evidence links ghrelin to glucose metabolism and metabolic syndrome.
Purpose of the Study:
- To review the potential of ghrelin as a therapeutic target.
- To discuss the limitations of targeting the ghrelin system.
- To explore ghrelin's role in understanding, preventing, and treating obesity and diabetes.
Main Methods:
- Literature review of ghrelin's physiological roles.
- Analysis of ghrelin signaling in metabolic disorders.
- Evaluation of ghrelin antagonists as therapeutic agents.
Main Results:
- Ghrelin significantly impacts appetite, body weight, and glucose homeostasis.
- The ghrelin signaling system is implicated in metabolic syndrome.
- Blocking ghrelin signaling presents a promising therapeutic strategy.
Conclusions:
- Ghrelin is a key regulator of energy balance and glucose metabolism.
- The ghrelin system is a viable target for novel obesity and diabetes treatments.
- Further research is needed to fully understand and leverage ghrelin's therapeutic potential.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...